drugset / Trial / NCT00808223
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis.
Timeline
- Start
- 2009-04
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alefacept | Protein / enzyme biologic | — | Intramuscular |